GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer

Jinli Wei(Fudan University Shanghai Cancer Center), Zhi‐Ming Shao(Fudan University)

Journal for ImmunoTherapy of Cancer

July 1, 2021

10.1136/jitc-2021-002383

Cited by 55

Related Papers

Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients

|Nature Communications|2018|183

Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy

|Oncotarget|2015|36

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer

|International Journal of Nanomedicine|2015|21

A polymorphism in JMJD2C alters the cleavage by caspase-3 and the prognosis of human breast cancer

|Oncotarget|2014|19

In vivo <scp>CRISPR</scp> screens identify <scp>RhoV</scp> as a <scp>pro‐metastasis</scp> factor of <scp>triple‐negative</scp> breast cancer

|Cancer Science|2023|12